AR075041A1 - Composicion farmaceutica que contiene aleglitazar, proceso, uso. - Google Patents
Composicion farmaceutica que contiene aleglitazar, proceso, uso.Info
- Publication number
- AR075041A1 AR075041A1 ARP100100131A ARP100100131A AR075041A1 AR 075041 A1 AR075041 A1 AR 075041A1 AR P100100131 A ARP100100131 A AR P100100131A AR P100100131 A ARP100100131 A AR P100100131A AR 075041 A1 AR075041 A1 AR 075041A1
- Authority
- AR
- Argentina
- Prior art keywords
- aleglitazar
- pharmaceutical composition
- composition containing
- salt
- composition obtained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Reivindicacion 1: Composicion farmacéutica que contiene del 0,01 mg al 0,9 mg de aleglitazar o una sal del mismo que puede fabricarse (a) pulverizando una solucion que contiene aleglitazar o una sal del mismo sobre un diluyente y un desintegrante; (b) mezclando la composicion obtenida en el paso (a) con un lubricante; y (c) opcionalmente comprimiendo la composicion obtenida en el paso (b). Reivindicacion 17: Uso de una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones de 1 a 16 caracterizado porque es para la preparacion de un medicamento para el tratamiento o profilaxis de la diabetes de tipo 2 o de enfermedades cardiovasculares.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09151254 | 2009-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075041A1 true AR075041A1 (es) | 2011-03-02 |
Family
ID=42112184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100131A AR075041A1 (es) | 2009-01-23 | 2010-01-21 | Composicion farmaceutica que contiene aleglitazar, proceso, uso. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20100190835A1 (es) |
| EP (1) | EP2389166B1 (es) |
| JP (1) | JP5619027B2 (es) |
| KR (2) | KR20140002812A (es) |
| CN (1) | CN102292074B (es) |
| AR (1) | AR075041A1 (es) |
| AU (1) | AU2010206249B2 (es) |
| BR (1) | BRPI1007237B1 (es) |
| CA (1) | CA2748896C (es) |
| CL (1) | CL2011001777A1 (es) |
| CY (1) | CY1113641T1 (es) |
| DK (1) | DK2389166T3 (es) |
| ES (1) | ES2397558T3 (es) |
| HR (1) | HRP20130108T1 (es) |
| IL (1) | IL213671A (es) |
| MX (1) | MX2011007381A (es) |
| PE (2) | PE20120421A1 (es) |
| PL (1) | PL2389166T3 (es) |
| PT (1) | PT2389166E (es) |
| RU (1) | RU2537224C2 (es) |
| SG (1) | SG173058A1 (es) |
| SI (1) | SI2389166T1 (es) |
| TW (1) | TWI406861B (es) |
| WO (1) | WO2010084066A1 (es) |
| ZA (1) | ZA201104670B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013181384A1 (en) | 2012-05-31 | 2013-12-05 | Ratiopharm Gmbh | Solid state forms of aleglitazar sodium |
| WO2014016369A1 (en) | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Pharmaceutical formulation comprising aleglitazar and complexing agent |
| WO2014016371A1 (en) | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Micronized aleglitazar |
| WO2014016370A1 (en) * | 2012-07-27 | 2014-01-30 | Ratiopharm Gmbh | Amorphous aleglitazar |
| MX2015002095A (es) * | 2012-09-12 | 2015-05-11 | Hoffmann La Roche | Formas solidas de acido (s)-2-metoxi-3-{4-[2-(5-metil-2-fenil-oxaz ol-4-il)-etoxi]benzo[b]tiofen-7-il}propionico y de sales del mismo. |
| CN116172869A (zh) * | 2016-08-10 | 2023-05-30 | 豪夫迈·罗氏有限公司 | 包含Akt蛋白激酶抑制剂的药物组合物 |
| CN114404375B (zh) * | 2022-01-21 | 2023-06-27 | 武汉九珑人福药业有限责任公司 | 一种叶酸固体制剂及其原料组合物、制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| MXPA03010435A (es) * | 2001-05-15 | 2004-03-09 | Hoffmann La Roche | Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes. |
| GB0303600D0 (en) * | 2003-02-17 | 2003-03-19 | Glaxo Group Ltd | Novel therapeutic method and compositions |
| US7262303B2 (en) * | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
| US20060051413A1 (en) * | 2004-09-08 | 2006-03-09 | Chow Sing S M | Method of enhancing absorptions of transmucosal administration formulations |
| KR20070094666A (ko) * | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
| US20060270722A1 (en) * | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
| FR2894477A1 (fr) * | 2005-12-13 | 2007-06-15 | Galderma Res & Dev | Utilisation du naveglitazar pour la preparation d'une composition pharmaceutique destinee au traitement des affections dermatologiques |
| US20100210692A1 (en) * | 2007-03-28 | 2010-08-19 | Farmer Stephen R | Methods of treatment using sirt modulators and compositions containing sirt1 modulators |
-
2010
- 2010-01-13 KR KR1020137032602A patent/KR20140002812A/ko not_active Ceased
- 2010-01-13 AU AU2010206249A patent/AU2010206249B2/en not_active Ceased
- 2010-01-13 EP EP10701340A patent/EP2389166B1/en not_active Not-in-force
- 2010-01-13 CN CN2010800050015A patent/CN102292074B/zh not_active Expired - Fee Related
- 2010-01-13 PE PE2011001309A patent/PE20120421A1/es not_active Application Discontinuation
- 2010-01-13 JP JP2011546748A patent/JP5619027B2/ja not_active Expired - Fee Related
- 2010-01-13 CA CA2748896A patent/CA2748896C/en not_active Expired - Fee Related
- 2010-01-13 ES ES10701340T patent/ES2397558T3/es active Active
- 2010-01-13 DK DK10701340.1T patent/DK2389166T3/da active
- 2010-01-13 BR BRPI1007237-3A patent/BRPI1007237B1/pt not_active IP Right Cessation
- 2010-01-13 KR KR1020117016128A patent/KR20110105798A/ko not_active Ceased
- 2010-01-13 PL PL10701340T patent/PL2389166T3/pl unknown
- 2010-01-13 MX MX2011007381A patent/MX2011007381A/es active IP Right Grant
- 2010-01-13 SI SI201030129T patent/SI2389166T1/sl unknown
- 2010-01-13 RU RU2011134964/15A patent/RU2537224C2/ru not_active IP Right Cessation
- 2010-01-13 SG SG2011052305A patent/SG173058A1/en unknown
- 2010-01-13 HR HRP20130108AT patent/HRP20130108T1/hr unknown
- 2010-01-13 WO PCT/EP2010/050343 patent/WO2010084066A1/en not_active Ceased
- 2010-01-13 PT PT107013401T patent/PT2389166E/pt unknown
- 2010-01-13 PE PE2016000386A patent/PE20160746A1/es unknown
- 2010-01-19 US US12/689,296 patent/US20100190835A1/en not_active Abandoned
- 2010-01-21 AR ARP100100131A patent/AR075041A1/es not_active Application Discontinuation
- 2010-01-22 TW TW099101817A patent/TWI406861B/zh not_active IP Right Cessation
-
2011
- 2011-06-20 IL IL213671A patent/IL213671A/en unknown
- 2011-06-23 ZA ZA2011/04670A patent/ZA201104670B/en unknown
- 2011-07-22 CL CL2011001777A patent/CL2011001777A1/es unknown
-
2012
- 2012-11-12 US US13/674,310 patent/US20130072529A1/en not_active Abandoned
- 2012-12-03 CY CY20121101181T patent/CY1113641T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501079A1 (en) | 1,3-thiazol-2-yl substituted benzamides | |
| AR075041A1 (es) | Composicion farmaceutica que contiene aleglitazar, proceso, uso. | |
| MX386981B (es) | Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7). | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| EA201100896A1 (ru) | Композиция, предназначенная для всасывания никотина из ротовой полости с целью прекратить курение | |
| AR089931A1 (es) | Composiciones farmaceuticas que contienen dimetilfumarato | |
| ECSP11011456A (es) | Inhibidores de la replicación viral novedosos | |
| DOP2016000253A (es) | Nuevos compuestos | |
| CL2012003211A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas | |
| EA201291410A1 (ru) | Фармацевтические композиции, содержащие 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1h-бензимидазол-2-ил]-1h-хинолин-2-она лактат моногидрат | |
| CL2012000319A1 (es) | Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. | |
| CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
| AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| CO2019006652A2 (es) | Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1 | |
| UY35848A (es) | Tienopirimidinas | |
| CL2015000848A1 (es) | Uso de un compuesto de propilmetilfenol, o una composición que lo comprende, para producir una composición farmacéutica y/o nutracéutica para el tratamiento y/o profilaxis de la anemia infecciosa del salmón (isa) (divisional sol. n° 2654-12). | |
| CL2011003123A1 (es) | Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras. | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| CO7170181A2 (es) | Nueva composición de alfentanilo para el tratamiento del dolor agudo | |
| IN2012DN00977A (es) | ||
| WO2010086617A3 (en) | Phosphoantigens for the treatment of burkholderia infections | |
| AR074470A1 (es) | Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes | |
| CO2018010142A2 (es) | Proceso de preparación de fórmulas solidas de mesalazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |